AstraZeneca Fails to Keep Generic Crestor Rivals Off Market

Updated on
  • Company can’t stop copies of its $5 billion cholesterol pill
  • Federal judge denied request to temporarily block FDA ruling

AstraZeneca Plc can’t stop generic-drug makers from bringing cheaper rivals of its best-selling medicine, the cholesterol fighter Crestor, to the U.S. market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.